Agilent Technologies Inc. - A STOCK NEWS

Agilent Technologies Inc. (NYSE: A) will present at two major healthcare conferences: the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022 at 11 a.m. ET and the J.P. Morgan 40th Annual Healthcare Conference on January 11, 2022 at 4:30 p.m. ET. Presentations will be made by CEO Mike McMullen and CFO Bob McMahon. Both events will be webcast, and further details can be found on Agilent's Investor Relations page. The company reported $6.32 billion in revenue for fiscal 2021.

Agilent Technologies Inc. (NYSE: A) has introduced compatibility of its Cary 3500 UV-Vis Spectrophotometer with the Agilent OpenLab software suite. This integration facilitates secure data management and compliance with global regulatory standards, addressing concerns highlighted in a recent survey about data integrity in pharma labs. The system enhances data security and improves efficiency by allowing simultaneous data collection and calibration in under five seconds. Agilent aims to support GMP labs in minimizing audit risks.

Agilent Technologies (NYSE: A) announced its participation in the Evercore ISI Virtual Healthcare Conference on December 1, 2021, at 11:20 a.m. ET. CEO Mike McMullen and CFO Bob McMahon will represent the company. The presentation will be available via webcast, with access links on Agilent's Investor Relations page. In fiscal 2021, Agilent generated $6.32 billion in revenue and employs around 17,000 employees globally.

Agilent Technologies reported a record-setting performance for fiscal year 2021, with fourth-quarter revenue of $1.66 billion, reflecting a 12% growth. The GAAP net income reached $442 million, resulting in an EPS of $1.45, a significant 104% increase year-over-year. For fiscal 2021, total revenue was $6.32 billion, an 18% increase, and full-year net income was $1.21 billion, with an EPS of $3.94.

Looking ahead, Agilent expects 2022 revenue between $6.65 billion and $6.73 billion, with first-quarter revenue guidance of <$1.64 billion to $1.66 billion.

Agilent Technologies (NYSE: A) has appointed Dr. Otis W. Brawley, a leading authority in oncology, to its board of directors, effective November 17, 2021. Dr. Brawley, who is affiliated with Johns Hopkins University, brings extensive expertise in cancer screening and prevention, focusing on reducing disparities in cancer care. His prior roles include chief medical and scientific officer at the American Cancer Society. Agilent's CEO, Mike McMullen, emphasized that Dr. Brawley's insights will enhance Agilent's cancer diagnostics focus, positioning the company as a leader in this area.

Agilent Technologies (NYSE: A) has announced an 8% increase in its quarterly dividend, raising it to 21 cents per share. This dividend will be payable on January 26, 2022, to shareholders on record as of January 4, 2022. The company reported $5.34 billion in revenue for fiscal year 2020 and employs approximately 16,400 people globally. Future dividends will be subject to board approval.

Agilent Technologies (NYSE: A) announced the appointment of John Palma as vice president of Medical Affairs. With over 26 years in diagnostics and research, Palma will lead the companywide Global Medical Affairs organization, focusing on liquid biopsy development. His prior experience includes senior roles at Roche, enhancing Agilent's position in cancer diagnostics and precision oncology. This strategic move follows Agilent's acquisition of Resolution Bioscience, demonstrating a commitment to advancing capabilities in next-generation sequencing.

Agilent Technologies (NYSE: A) has launched the new 6560C Ion Mobility LC/Q-TOF, enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges. These innovations support biopharma research, enhancing the analysis of proteins and peptides, crucial for developing new therapeutics. They address regulatory compliance and improve data integrity. Agilent's solutions are showcased at the American Society for Mass Spectrometry Conference from October 31 to November 4, 2021, in Philadelphia.

Agilent Technologies (NYSE: A) announced that its PD-L1 IHC 22C3 pharmDx assay is now approved for identifying triple-negative breast cancer (TNBC) patients eligible for treatment with KEYTRUDA® in Europe. PD-L1 expression is crucial for anti-PD-1 therapy responses. The assay, already used in four other cancer types, enhances pathologists' ability to identify suitable patients. With over 530,000 new breast cancer cases in Europe in 2020, this approval significantly expands Agilent's diagnostic capabilities, reinforcing its leadership in companion diagnostics.